NCT00872326View on ClinicalTrials.gov

Autologous Bone Marrow Derived Mononuclear Cells in Treating Diabetic Patients With Critical Limb Ischemia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

April 30, 2009

Study Completion Date

May 31, 2009

Conditions
Peripheral Vascular DiseasesDiabetic Foot
Interventions
PROCEDURE

Autologous Bone Marrow Mononuclear Cells

Infusion \> 80 millions mononuclear cells. Intraarterial administration at popliteal artery level. Infusion during 3 minutes with antegrade blockage of arterial flow.

Trial Locations (1)

41007

University Hospital Virgen Macarena, Seville

All Listed Sponsors
collaborator

Carlos III Health Institute

OTHER_GOV

lead

Andalusian Network for Design and Translation of Advanced Therapies

OTHER

NCT00872326 - Autologous Bone Marrow Derived Mononuclear Cells in Treating Diabetic Patients With Critical Limb Ischemia | Biotech Hunter | Biotech Hunter